The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
MERCK

History

When Merck launched its AIDS research program in January 1987, the pressure to find new treatments for HIV was already mounting from all sides.

The following timeline shows how events unfolded in the development of CRIXIVAN, and how this new class of antiretroviral drugs caused all parties concerned to rethink precedents set in the past.

CRIXIVAN history timeline 1987 - Search for inhibitor begins 1988 - Irving Sigal dies in Pan Am 103 1990 - First test on dogs 1991 - Community advisory board established 1992 - Compound found 1993 - First human trials of CRIXIVAN begin 1994 - Resistance detected; dosage increased 1995 - Phase III testing begun 1996 - Test results presented. FDA approves CRIXIVAN
This site is intended only for healthcare professionals of the United States, its territories, and Puerto Rico.

CRIXIVAN is a registered trademark of Merck & Co., Inc.
20350665(2)-11/03-CRX